The effect of systemically administered recombinant human nerve growth factor in healthy human subjects.

@article{Petty1994TheEO,
  title={The effect of systemically administered recombinant human nerve growth factor in healthy human subjects.},
  author={Brent G. Petty and David Reid Cornblath and Bruce T. Adornato and Vinay Chaudhry and Charles Flexner and Monica Wachsman and Dominick V Sinicropi and Louis E. Burton and Stephen J. Peroutka},
  journal={Annals of neurology},
  year={1994},
  volume={36 2},
  pages={244-6}
}
This phase I double-masked, randomized, placebo-controlled study evaluated the safety of single intravenous or subcutaneous doses of recombinant human nerve growth factor (rhNGF) in healthy human volunteers at doses ranging from 0.03 to 1 micrograms/kg. No life-threatening adverse events were seen at any dose. At doses above 0.1 microgram/kg, subjects reported mild to moderate muscle pain, primarily in the bulbar and truncal musculature. The duration and severity of these myalgias varied in a… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 90 extracted citations

NGF/TrkA Signaling as a Therapeutic Target for Pain.

Pain practice : the official journal of World Institute of Pain • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…